Genes & biomarkers
FLT3 variants
FLT3 · ITD / TKD
An AML target where variant type and treatment setting matter.
Sources checked · Introductory guide
On this page
What does this result mean?
FLT3 helps regulate blood cell growth. AML may carry changes such as ITD or TKD; the alteration type should be read explicitly in the report.[1]
How does it connect to treatment?
Gilteritinib is used in adults with FLT3-mutated relapsed/refractory AML. Initial and relapse treatment have different criteria, so check the qualifying variants and setting for each drug.[2]
What should I check in my report?
Check ITD versus TKD and the test date. Ask whether repeat testing at relapse is needed and how this result fits with other genes and marrow findings.
Questions for your care team
- Which inhibitor fits my FLT3 alteration and current treatment setting?
- Which treatments or trials fit my cancer type, stage and previous treatment?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.